Simple Summary Chemotherapy, radiotherapy and molecularly targeted therapy could
improve the prognosis of colorectal cancer (CRC) patients. Recently, immunotherapy …

MYC regulates multiple gene programs, raising questions about the potential selectivity and
downstream transcriptional consequences of MYC inhibitors as cancer therapeutics. Here …

MYC is a critical growth regulatory gene that is commonly overexpressed in a wide range of
cancers. Therapeutic targeting of MYC transcriptional activity has long been a goal, but it …

The WNT pathway is a fundamental regulator of intestinal homeostasis, and hyperactivation
of WNT signaling is the major oncogenic driver in colorectal cancer. To date, there are no …

Cyclin‐dependent kinases (CDK) are rational cancer therapeutic targets fraught with the
development of acquired resistance by tumor cells. Through metabolic and transcriptomic …

MYC can be considered to be one of the most pressing and important targets for the
development of novel anti-cancer therapies. This is due to its frequent dysregulation in …

Cancer cells alter their metabolism for the production of precursors of macromolecules.
However, the control mechanisms underlying this reprogramming are poorly understood …

Resistance to anti-cancer treatments is a critical and widespread health issue that has
brought serious impacts on lives, the economy and public policies. Mounting research has …

Several years ago, we described Myc as “the oncogene from hell”, since evidence had just
emerged that Myc, aside from being responsible for cell-cycle progression and tumor …

Tumor profiling and targeted therapy revolutionized the treatment strategies of metastatic
colorectal cancer (mCRC) in the last decade. The heterogeneity of CRC tumors plays a …